13F reference period
Q2 2026
Security Snapshot
Eton Pharmaceuticals, Inc. - Common Stock (ETON) Institutional Ownership
CUSIP: 29772L108
13F Institutional Holders and Ownership History from Q4 2018 to Q3 2026
Institutions Reporting
163
Shares (Excl. Options)
19,964,943
Price
$36.20
The headline uses the Q2 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended. Newer periods in the history table contain incoming reports and may be incomplete.
Save this security page for your next review
Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock
- Symbol
- ETON on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 19,964,943
- Total 13F value
- $722,555,230
- Portfolio coverage rank
- 0%
- Share change
- +2,160,512
- Value change
- +$80,491,573
- Number of holders
- 163
- Underlying class
- Common Stock
- Shares outstanding
- 27,281,304
- SEC-reported price per share
- $51.49
- Insider filing price
- $51.49
Latest holder snapshot
5 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source
Key facts
- ETON - Eton Pharmaceuticals, Inc. - Common Stock is tracked under CUSIP 29772L108.
- 163 institutions reported positions in Q2 2026.
- 2 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 115 to 163 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $438,556,434 to $722,555,230.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 163 institutions filings for Q2 2026.
Security key
29772L108
13F reference period
Q2 2026
13F holders
163
13D/G owners
2
CIK / CUSIP context first
Open Q2 2026 holders
ETON full holder history
Eton Pharmaceuticals, Inc. SEC filings
Eton Pharmaceuticals, Inc. company facts
Eton Pharmaceuticals, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 29772L108:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
2
Security
ETON
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| EcoR1 Capital, LLC | 7.7% | $28,407,583 | 1,981,003 | EcoR1 Capital, LLC | 31 Dec 2024 | |||
| BlackRock, Inc. | 6.9% | +20% | $68,143,242 | +$12,744,319 | 1,882,410 | +23% | BlackRock, Inc. | 30 Jun 2026 |
As of 30 Jun 2026, 163 institutional investors reported holding 19,964,943 shares of Eton Pharmaceuticals, Inc. - Common Stock (ETON). This represents 73% of the company’s total 27,281,304 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
59%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Opaleye Management Inc. | 10% | 2,860,000 | 0% | 9.4% | $103,532,000 |
| EcoR1 Capital, LLC | 8% | 2,171,938 | 0% | 3.9% | $78,624,156 |
| BlackRock, Inc. | 6.9% | 1,895,833 | +10% | 0% | $68,629,156 |
| Nantahala Capital Management, LLC | 4.3% | 1,175,951 | 0% | 2.6% | $42,569,426 |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.6% | 976,570 | -1.8% | 0% | $35,351,834 |
| MORGAN STANLEY | 2.8% | 767,972 | +61% | 0% | $27,800,585 |
| STATE STREET CORP | 2.6% | 701,786 | +32% | 0% | $25,404,653 |
| GEODE CAPITAL MANAGEMENT, LLC | 2.4% | 652,303 | +13% | 0% | $23,618,970 |
| OBERWEIS ASSET MANAGEMENT INC/ | 1.8% | 501,600 | +14% | 0.38% | $18,157,920 |
| National Philanthropic Trust | 1.8% | 492,112 | 0% | 0.26% | $17,814,454 |
| Westside Investment Management, Inc. | 1.6% | 431,160 | -7.9% | 2.1% | $15,608,010 |
| Pillsbury Lake Capital LLC | 1.4% | 387,157 | +6.1% | 3.9% | $14,015,083 |
| Nuveen, LLC | 1.4% | 375,707 | +548% | 0% | $13,600,593 |
| BNP PARIBAS FINANCIAL MARKETS | 1.2% | 322,466 | 0% | 0.01% | $11,673,269 |
| Woodline Partners LP | 1.1% | 310,879 | +82% | 0.03% | $11,253,820 |
| THOMPSON SIEGEL & WALMSLEY LLC | 1.1% | 297,232 | -27% | 0.19% | $10,760,000 |
| NORTHERN TRUST CORP | 0.94% | 255,849 | +7.6% | 0% | $9,261,733 |
| MARSHALL WACE, LLP | 0.91% | 249,182 | +201% | 0.01% | $9,020,387 |
| Panoramic Capital, LLC | 0.76% | 208,192 | +13% | 3.2% | $7,536,550 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 0.71% | 194,591 | +28% | 0% | $7,044,194 |
| JPMORGAN CHASE & CO | 0.7% | 191,635 | +13% | 0% | $7,038,753 |
| D. E. Shaw & Co., Inc. | 0.69% | 188,452 | 0% | $6,821,962 | |
| JANE STREET GROUP, LLC | 0.68% | 185,697 | +95% | 0% | $6,722,232 |
| Lumbard & Kellner, LLC | 0.64% | 175,909 | -0% | 1.9% | $6,367,906 |
| CANNELL CAPITAL LLC | 0.63% | 170,747 | -50% | 4.3% | $6,181,041 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
32
Headline period
Q2 2026
Rows shown
1-25 of 32
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q3 | 319,941 | $16,472,511 | +$4,187,770 | $51.49 | 31 |
| 2026 Q2 | 19,964,943 | $722,555,230 | +$80,491,573 | $36.20 | 163 |
| 2026 Q1 | 17,784,208 | $438,556,434 | +$36,598,155 | $24.68 | 115 |
| 2025 Q4 | 16,409,932 | $277,512,848 | -$34,675,068 | $16.91 | 104 |
| 2025 Q3 | 17,672,584 | $384,025,414 | +$22,957,486 | $21.73 | 101 |
| 2025 Q2 | 16,549,306 | $235,826,915 | +$35,134,963 | $14.25 | 85 |
| 2025 Q1 | 14,123,114 | $183,315,077 | +$11,955,184 | $12.98 | 85 |
| 2024 Q4 | 13,135,396 | $174,958,469 | +$42,338,294 | $13.32 | 70 |
| 2024 Q3 | 9,507,414 | $57,043,272 | +$8,311,784 | $6.00 | 47 |
| 2024 Q2 | 8,228,308 | $27,068,977 | +$3,401,849 | $3.29 | 44 |
| 2024 Q1 | 7,182,688 | $26,933,962 | -$87,277 | $3.75 | 43 |
| 2023 Q4 | 7,158,411 | $31,363,548 | +$1,218,504 | $4.38 | 55 |
| 2023 Q3 | 6,899,800 | $28,769,681 | +$3,931,364 | $4.17 | 50 |
| 2023 Q2 | 5,976,427 | $20,857,388 | +$424,606 | $3.49 | 33 |
| 2023 Q1 | 5,838,481 | $22,478,563 | +$148,362 | $3.85 | 34 |
| 2022 Q4 | 5,937,571 | $18,150,958 | -$813,830 | $2.82 | 31 |
| 2022 Q3 | 6,343,985 | $13,321,785 | +$813,651 | $2.10 | 29 |
| 2022 Q2 | 5,916,510 | $17,660,917 | +$786,718 | $2.62 | 28 |
| 2022 Q1 | 5,783,483 | $27,369,526 | +$1,310,432 | $4.36 | 29 |
| 2021 Q4 | 5,731,001 | $24,586,557 | -$1,088,577 | $4.29 | 30 |
| 2021 Q3 | 5,962,287 | $32,572,856 | -$1,717,167 | $5.04 | 35 |
| 2021 Q2 | 3,148,485 | $22,473,059 | -$10,316,735 | $6.16 | 42 |
| 2021 Q1 | 8,785,097 | $67,961,804 | +$530,664 | $7.32 | 48 |
| 2020 Q4 | 8,725,390 | $74,997,463 | +$13,790,621 | $8.13 | 45 |
| 2020 Q3 | 7,034,912 | $59,521,869 | +$2,214,437 | $7.90 | 38 |